01779 天辰生物－Ｂ
LONGBIO-B
LONGBIO-B
| Register Close | 2026/06/02 IPO Closing in 2 Days |
| Listing Date | 2026/06/05 |
|
|
|
|
|
|
|
|
|
|
IPO Detail
COMPANY PROFILE
LongBio Pharma (Suzhou) Co. is a clinical-stage biopharmaceutical company. Established in 2020 and located in Shanghai and Changshu, Suzhou, China, the Group primarily focuses on in-house discovery and development of biopharmaceuticals targeting allergic and autoimmune diseases.
--
The Group has one Core Product, LP-003, an anti-IgE antibody with the primary function of blocking free IgE in blood and tissues, and thus inhibiting the occurrence of IgE-driven allergic reactions, which is targeted to treat allergic diseases, including seasonal allergic rhinitis (AR), chronic spontaneous urticaria (CSU), allergic asthma and other allergic diseases; and one Key Product, LP-005, a bi-functional antibody fusion protein targeting C5 and C3b complement, which is targeted for the treatment of related renal and hematologic indications.
--
The Group’s Core Product LP-003 and its Key Product LP-005 are under clinical development with IND approvals from CDE. As of May 18, 2026, the Group owned eight granted patents, it also has 29 patent applications relating to certain of its drug candidates and product development technologies.
BASIC INFORMATION
| Market | Hong Kong (Main Board) |
| Business Nature | Health Care |
| Major Business Area | China |
| Board Lot | 50 |
GLOBAL OFFERING
| No. of Offer Shares | 14.19M H shares |
| No. of International Offer Shares | 12.77M H shares |
| No. of HK Offer Shares | 1.42M H shares |
| Offer Price | $96.06 |
| Stock Code | 1779 |
| Sponsor(s) | Sinolink Securities (Hong Kong) Company Limited |
| Underwriter(s) | Sinolink Securities (Hong Kong) Company Limited, GF Securities (Hong Kong) Brokerage Limited, ABCI Securities Company Limited, CCB International Capital Limited, Shanxi Securities International Limited, TradeGo Markets Limited |
TIME TABLE
| Application Period | May 28 (Thu) - noon, Jun 02 (Tue) |
| Price Determination Date | -- |
| Result Announcement Date | On or before Jun 04 (Thu) |
| Result Announcement Date | On or before Jun 04 (Thu) |
| Result Announcement Date | On or before Jun 05 (Fri) |
| Dealings in Shares commence on | Jun 05, 2026. (Fri) |
Reallocation of Shares Offered
Sales Statistics (HKD)
| Offer Price | $96.06 |
| Capitalization (H Shares) | 7.01B |
| NAV / share ($) | $19.37 (Unaudited pro forma adj NAV / share) |
Use Of Proceeds
| Assuming the offer price being at HKD 96.06, the net proceeds raised would be HKD 1.25B, of which |
| 34% : R&D of Core Product LP-003 |
| 13% : Commercialization of LP-003 for seasonal AR indication in China |
| 28% : Research and development of Key Product LP-005 |
| 11.8% : Pre-clinical studies and clinical development of other pipeline products |
| 3.2% : Further development of R&D platforms and exploration of new drugs |
| 10% : Working capital |
Related Document
| Prospectus |  Chinese Version | English Version |
| Remark： | The above information is referenced from the prospectus. |
| All data is calculated from the non- exercise rights(if applicable). |
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --Offer Price︰--
| Currency | : |
| Listing Price | : |
| Board Lot | : |
| Admission Fee* |
: |
| Subscribing Lot | : |
| Subscribing Fee | : |
| Subscribing Amount | : |
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).